Dhaher Samer A; Alhamdi Dhoha Kh
Abstract
Background: Rosacea is a chronic inflammatory disease of unknown etiology. Few studies have been published on the use of oral ivermectin in the treatment of the inflammatory subset of rosacea. The aim of the present research was to evaluate the efficacy and safety of oral ivermectin prescribed for a ...
Read More
Background: Rosacea is a chronic inflammatory disease of unknown etiology. Few studies have been published on the use of oral ivermectin in the treatment of the inflammatory subset of rosacea. The aim of the present research was to evaluate the efficacy and safety of oral ivermectin prescribed for a series of patients with inflammatory rosacea.
Methods: On a weekly basis, 29 patients with papulopustular rosacea were orally given ivermectin at a dose of 200 µg/kg before meal for three consecutive weeks. Subjects were evaluated weekly and during the follow-up period for two successive treatment-free months.
Results: After 3 doses of ivermectin, there was a significant reduction in the total count of inflammatory lesions compared to the base line (the mean was reduced from 51.6±27.4 to 21±14.7) (P<0.05). At the end of the two-month follow-up period, more reduction was observed in inflammatory lesions (mean was reduced to 9.3±7), and 62% of the patients showed excellent responses to the treatment (≥ 80% reduction in the lesions). Nausea was reported in 10%.
Conclusion: A three-week use of oral ivermectin is an effective, safe, and well-tolerated approach to treating inflammatory rosacea .
Mapar Mohammad Ali; Mali Behrooz
Volume 11, Issue 4 , 2008, , Pages 147-150
Abstract
Background: Scabies is a common skin disease and a public health problem. The topical antiscabietics have a poor compliance. The aim of this study was to compare the efficacy of oral Ivermectin with topical Lindane solution in the treatment of scabies. Methods: This was a prospective comparative open ...
Read More
Background: Scabies is a common skin disease and a public health problem. The topical antiscabietics have a poor compliance. The aim of this study was to compare the efficacy of oral Ivermectin with topical Lindane solution in the treatment of scabies. Methods: This was a prospective comparative open study. Fifty seven patients were randomized in two groups. One group (32 patients) received 200µg/kg body weight of Ivermectin in two oral doses with a one-week interval, and the second group, (25 patients) received 2 consecutive weekly topical applications of Lindane. All patients were followed up for 2 weeks. Results: A single oral dose of Ivermectin cured 72% of patients and 91% of the patients were cured after the second dose. Two applications of Lindane with a one-week interval cured 92% of cases. Conclusion: Compared to topical Lindane in the treatment of scabies, Ivermectin was at least as effective as Lindane.
M Eslami Danesh Pajooh; F Jafari; M Farivar Sadri; M Valikhani
Volume 3, Issue 2 , 2000, , Pages 10-15
Abstract
Background: Oral ivermectin is recently introduced for the treatment of scabies. Objective: The objective of this clinical trial was to compare the efficacy and safety of oral ivermectin and topical Gamma Benzene Hexachloride (GBH) 1% for the treatment of scabies. Patients and Methods: Fifty-eight cases ...
Read More
Background: Oral ivermectin is recently introduced for the treatment of scabies. Objective: The objective of this clinical trial was to compare the efficacy and safety of oral ivermectin and topical Gamma Benzene Hexachloride (GBH) 1% for the treatment of scabies. Patients and Methods: Fifty-eight cases were randomly assigned in the two treatment groups. In the ivermectin group, patients received a single oral dose of the drug (200 µg/kg). In the case of any signs of active disease, a second dose was administered one week later. All the patients in the GBH group received two topical applications of the drug, one week apart. The patients were seen after 48 hours, 1, 2, and 4 weeks. Results: Of the 37 patients treated with ivermectin, 27 (73%) showed clinical cure with a single dose and 10 (27%) required a second dose one week later. In the 21 patients treated with GBH, 18 (85.7%) received two applications of GBH, and three cases (14.3%) were cured by an additional curse of precipitated sulfur 6%. No serious side effects were seen in either group. The mean time for the drop of pruritus, the sense of well being and the healing of lesions, were each shorter with ivermectin than GBH, and the differences were statistically significant. Conclusion: Although all of the patients treated with ivermectin or topical GBH were cured, ivermectin cured faster than topical treatment.
